UTHR (United Therapeutics) Construction In Progress: $704 Mil (As of Mar. 2026)


UTHR United Therapeutics Corp UTHR
88 GF Score
Price $550.82
GF Value $386.36
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Construction In Progress?

United Therapeutics UTHR +0.17% 88 Construction In Progress is $704 Mil as of Mar. 2026. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.36 (Significantly Overvalued). The stock has 7 warning signs investors should review.

United Therapeutics's quarterly construction in progress increased from Sep. 2025 ($440 Mil) to Dec. 2025 ($593 Mil) and increased from Dec. 2025 ($593 Mil) to Mar. 2026 ($704 Mil).

United Therapeutics's annual construction in progress declined from Dec. 2023 ($259 Mil) to Dec. 2024 ($218 Mil) but then increased from Dec. 2024 ($218 Mil) to Dec. 2025 ($593 Mil).

United Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Construction In Progress Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.10 110.90 259.10 218.20 592.70

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 276.80 328.70 440.00 592.70 704.20
UTHR
88GF Score
United Therapeutics Corp UTHR
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $704 Mil mean?
United Therapeutics (UTHR) has a Construction In Progress of $704 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Construction In Progress too high?
United Therapeutics' current Construction In Progress is $704 Mil. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Construction In Progress compare to VTRS and NBIX?
United Therapeutics' Construction In Progress of $704 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on United Therapeutics and its competitors. United Therapeutics's current Construction In Progress is $704 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.36, compared to a current price of $550.82 — trading 42.6% above its estimated fair value. The current Construction In Progress is $704 Mil. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Construction In Progress is $704 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $550.82 is trading 42.6% above its estimated GF Value™ of $386.36. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Construction In Progress: $704 Mil
  • GF Value™: $386.36 vs. price of $550.82 (42.6% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$550.82
Price
$386.36
GF Value